Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01177397
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:53.075184+00:00
Published At
2022-11-15T00:00:00+00:00
Record Updated At
2022-12-13
Results Posted At
2022-11-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Multiple Myeloma", "Diffuse Large B-Cell Lymphoma", "Glioblastoma Multiforme", "Hepatocellular Carcinoma", "Non-Small Cell Lung Cancer", "Neuroendocrine Tumors of Non-Pancreatic Origin", "Hormone Receptor-Positive Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-12-13"
protocolSection.identificationModule.nctId
"NCT01177397"
protocolSection.identificationModule.officialTitle
"A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-11-15"

Study condition terms

  • Multiple Myeloma (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Glioblastoma Multiforme (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Tumors of Non-Pancreatic Origin (protocolSection.conditionsModule.conditions)
  • Hormone Receptor-Positive Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.